Endocrinology and Nutrition Department, Málaga Institute of Biomedical Investigation (IBIMA), Málaga Regional University Hospital, Barcelona, Spain.
Medicine and Dermatology Department, School of Medicine, Málaga University, Barcelona, Spain.
J Diabetes. 2017 Jan;9(1):24-33. doi: 10.1111/1753-0407.12382. Epub 2016 Apr 13.
Although the insulin bolus calculator is increasingly being used by people with type 1 diabetes (T1D) on multiple daily injection (MDI) therapy, few studies have investigated its effects on glycemic control. The aim of this study was to determine whether adding this device to therapeutic intensification could further improve metabolic control.
A 4-month randomized controlled clinical trial was performed comparing subjects undergoing therapeutic intensification and either using the bolus calculator (Cb group) or not (active control [Co] group). Metabolic control, fear of hypoglycemia, and treatment acceptance were evaluated.
In all, 70 people completed the study (42 in the Cb group, 28 in the Co group). There was a significant decrease in HbA1c in both the Cb and Co groups (-7 mmol/mol [-0.7 %] vs -4 mmol/mol [-0.4 %], respectively). There were no significant differences in HbA1c at baseline or the end of the study, or in the decrease in HbA1c, glycemia, or changes in blood glucose levels at the end of the study between the two groups. There was a significant increase in the number of participants with good metabolic control (HbA1c <58 mmol/mol [7.5 %]) in the Cb group (from 16.7 % to 40.5 %), but not in the Co group. The incidence of hypoglycemic events was reduced slightly but significantly only in the Cb group. There was no change in the fear of hypoglycemia at the end of the study. The bolus calculator was well accepted.
In T1D, adding a bolus calculator to intensive MDI resulted in a significant improvement in metabolic control and slightly decreased the number of hypoglycemic episodes. Metabolic control also improved in the Co group.
尽管胰岛素推注计算器在接受多次每日注射(MDI)治疗的 1 型糖尿病(T1D)患者中越来越多地被使用,但很少有研究调查其对血糖控制的影响。本研究旨在确定在治疗强化过程中加入该设备是否能进一步改善代谢控制。
进行了一项为期 4 个月的随机对照临床试验,比较了接受治疗强化的患者,他们使用或不使用推注计算器(Cb 组)。评估了代谢控制、对低血糖的恐惧和治疗接受程度。
共有 70 人完成了研究(Cb 组 42 人,Co 组 28 人)。Cb 组和 Co 组的 HbA1c 均显著下降(分别为-7mmol/mol[-0.7%]和-4mmol/mol[-0.4%])。两组的基线和研究结束时的 HbA1c 无显著差异,HbA1c 的下降、血糖和研究结束时血糖水平的变化也无显著差异。在 Cb 组中,有良好代谢控制(HbA1c<58mmol/mol[7.5%])的参与者人数显著增加(从 16.7%增加到 40.5%),但 Co 组没有。只有 Cb 组的低血糖事件发生率略有但显著降低。研究结束时对低血糖的恐惧没有变化。推注计算器被很好地接受。
在 T1D 中,将推注计算器添加到强化 MDI 中可显著改善代谢控制,并略微减少低血糖发作次数。Co 组的代谢控制也有所改善。